Time-related changes in prevalence of chronic heart failure and diabetes mellitus in Nizhny Novgorod Region between 2000 and 2017

Aim. To determine time-related changes in prevalence, morbidity, and all-cause mortality of patients with CHF depending on the presence of DM in a representative sample of Nizhny Novgorod Region. Materials and methods. In 1998, a representative sample of Nizhny Novgorod Region was created, which included 1922 respondents. From 2000 through 2017, this sample was evaluated three times. Patients with CHF and DM were studied. Results. For 17 years, prevalence of NYHA FC IV CHF increased from 6.88 to 9.1% (р=0.04). Prevalence of NYHA FC III-IV CHF increased considerably from 1.2% to 4.8% (р<0.001). Morbidity of CHF patients increased from 10.8 to 16.4 per 1000 (р=0.02) and morbidity of DM patients increased from 3.7 to 6.6 per 1000 (р=0.03). DM significantly worsened the life prediction, particularly for patients with NYHA FC III-IV CHF. Conclusion. Prevalence of CHF is growing. Morbidity and all-cause mortality depend on the presence of DM and CHF FC severity. Risk for all-cause mortality increases following CHF decompensation no matter of the DM presence.

хроническая сердечная недостаточность, сахарный диабет, распространенность, заболеваемость, общая смертность, chronic heart failure, diabetes mellitus, prevalence, morbidity, all-cause mortality

1. Herman WH, Kalyani RR, Wexler DJ, Matthews DR, Inzucchi SE. Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes - 2016. Diabetes Care 2016;39 (Suppl. 1):S52 - S59. Diabetes Care. 2016;39 (6):e88-9. DOI:10.2337/dci16-0003

2. Giugliano D, Maiorino MI, Bellastella G, Esposito K. Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards ofMedical Care in Diabetes - 2016. Diabetes Care 2016;39 (Suppl. 1):S52 - S59. Diabetes Care. 2016;39 (6):e86-7. DOI:10.2337/dc15-2829

3. Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Current Diabetes Reports. 2013;13 (6):805-13. DOI:10.1007/s11892-013-0425-5

4. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U. S. Diabetes Care. 2006;29 (11):2415-9. DOI: 10.2337/dc06-1058

5. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews. 2004;25 (4):543-67. DOI:10.1210/er. 2003-0012

6. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice. 2016;115:90-5. DOI:10.1016/j. diabres. 2016.02.010

7. Jhund PS, MacIntyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119 (4):515-23. DOI:10.1161/CIRCULATIONAHA. 108.812172

8. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). The American Journal of Cardiology. 2008;101 (7):1016-22. DOI:10.1016/j. amjcard. 2007.11.061

9. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Журнал Сердечная Недостаточность. 2011;12 (2):63-8.

10. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20 (6):421-8.

11. Kistorp C, Galatius S, Gustafsson F, Faber J, Corell P, Hildebrandt P. Prevalence and characteristics of diabetic patients in a chro nic heart failure population. International Journal of Cardiology. 2005;100 (2):281-7. DOI:10.1016/j. ijcard. 2004.10.024

12. Kamalesh M, Subramanian U, Sawada S, Eckert G, Temkit M, Tierney W. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. European Journal of Heart Failure. 2006;8 (4):404-8. DOI:10.1016/j. ejheart. 2005.10.005

13. Kasznicki J, Drzewoski J. Heart failure in the diabetic population -pathophysiology, diagnosis and management. Arch Med Sci. 2014;10 (3):546-56. DOI: 10.5114/aoms. 2014.43748

14. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson A-M, Rosengren A. Glycaemic control and incidence of heart failure in 20985 patients with type 1 diabetes: an observational study. The Lancet. 2011;378 (9786):140-6. DOI:10.1016/S0140-6736 (11) 60471-6

15. Dedov II, Shestakova MV Mayorov AY, Vikulova OK, Galstyan GR, Kuraeva TL et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV Mayorov AY. 8th edition. Diabetes mellitus. 2017;20 (1S): 1-112. DOI:10.14341/DM20171S8

16. Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U. K. primary care setting. Diabetes Care. 2005;28 (1):20-6.

17. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. The Lancet. 2015;385 (9982):2107-17. DOI: 10.1016/S0140-6736 (14) 61402-1

18. Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Annals of Internal Medicine. 2016;164 (11):705. DOI:10.7326/M15-2568

19. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28 (10):2345-51.

20. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. European Journal of Heart Failure. 2008;10 (7):703 8. DOI:10.1016/j. ejheart. 2008.05.013

21. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339 (aug182):b2942 - b2942. DOI:10.1136/bmj. b2942

22. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017;18 (1):3-40

23. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. Journal of the American College of Cardiology. 2005;46 (6):1019-26. DOI:10.1016/j. jacc. 2005.02.093

24. Doehner W, Anker SD, Godsland IF. Optimizing insulin sensitivity assessment using the minimal model in chronic heart failure. Hormone and Metabolic Research. 2005;37 (2):106-10. DOI:10.1055/s-2005-861175

25. Мареев В. Ю., Беленков Ю. Н., Агеев Ф. Т., Фомин И. В., Хохлов Р. А., Галявич А. С. Первые результаты Российского эпидемиологического исследования по ХСН (ЭПОХА-ХСН). Журнал Сердечная Недостаточность. 2003;4 (1):17-8.

26. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Современный образ пациента с ХСН в Европейской части Российской Федерации (госпитальный этап). Журнал Сердечная Недостаточность. 2011;12 (5):255-9

27. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В., Карпов Ю. А., Белоусов Ю.Б. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по АГ и Всероссийского научного общества кардиологов). Системные Гипертензии. 2010; (3): 5-26

28. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med. 1977;31 (1):42-8.

29. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart disease and stroke statistics- - 2015 update: a report from the American Heart Association. Circulation. 2015;131 (4):e29-322.DOI:10.1161/CIR. 0000000000000152

30. Mejhert M, Persson H, Edner M, Kahan T. Epidemiology of heart failure in Sweden--a national survey. EurJ Heart Fail. 2001;3 (1):97-103.

31. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, DAgostino RB, Kannel WB et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106 (24):3068-72.

32. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137-46. DOI:10.1136/hrt. 2003.025270

33. Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. European Journal of Heart Failure. 2013,15 (9):995-1002. DOI:10.1093/eurjhf/hft064

34. Goldberg RJ, Spencer FA, Farmer C, Meyer TE, Pezzella S. Incidence and hospital death rates associated with heart failure: A community-wide perspective. The American Journal of Medicine. 2005,118 (7):728-34. DOI:10.1016/j. amjmed. 2005.04.013

35. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, et al. Long-term trends in the incidence of and survival with heart failure. N EnglJ Med. 2002,347 (18):1397-402. DOI:10.1056/NEJ-Moa020265

36. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012,380 (9859):2095-128. DOI:10.1016/S0140-6736 (12) 61728-0

37. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB et al. Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal. 2006,27 (1):65-75. DOI: 10.1093/eurheartj/ehi555

38. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008,29 (11):1377-85. DOI:10.1093/eurheartj/ehn153

39. Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P et al. Risk factor assessment for new onset diabetes: literature review. Diabetes, Obesity and Metabolism. 2009,11 (3):177-87. DOI:10.1111/j. 1463-1326.2008.00925. x

40. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail. 2013,15 (2):194-202. DOI:10.1093/eurjhf/hfs153

41. Gustafsson I, Brendorp B, Seibæk M, Burchardt H, Hildebrandt P, Kober L et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. Journal of the American College of Cardiology. 2004,43 (5):771 7. DOI:10.1016/j. jacc. 2003.11.024

42. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013,15 (7):808-17. DOI:10.1093/eurjhf/hft050

43. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В. и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация ХСНвреальной клинической практике (ЭПОХА-Д-ХСН). Журнал Сердечная Недостаточность. 2016,17 (6):299-305. DOI:10.18087/rhfj. 2016.5.2239